drugset / Trial / NCT05519410
Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a prospective, Two-arm, randomized，phase II clinical study of Sintilimab Combined With Lenvatinib Versus HAIC for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.
Timeline
- Start
- 2022-08-23
- Primary completion
- 2024-09-01
- Completion
- 2025-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | HAIC-FOLFOX | Unknown | 400 mg/m2 | Other |
| Subject | Lenvatinib | Small molecule | 8 mg/kg | Oral |
| Comparator | Oxa | Unknown | 85 mg/m2 | Other |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Comparator | fluorouracil | Small molecule | 400 mg/m2 | Other |
| Comparator | fluorouracil | Small molecule | 2400 mg/m2 | Other |